vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Forward Industries, Inc. (FWDI). Click either name above to swap in a different company.
Forward Industries, Inc. is the larger business by last-quarter revenue ($21.4M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -2732.2%, a 2731.4% gap on every dollar of revenue. On growth, Forward Industries, Inc. posted the faster year-over-year revenue change (224.0% vs -25.7%). Over the past eight quarters, Forward Industries, Inc.'s revenue compounded faster (74.6% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Melrose Industries plc is a British aerospace manufacturing company based in Birmingham, England. It is the parent company of GKN Aerospace. The company's shares are listed on the London Stock Exchange as a constituent of the FTSE 100 Index.
CTMX vs FWDI — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $21.4M |
| Net Profit | $-154.0K | $-585.7M |
| Gross Margin | — | 78.6% |
| Operating Margin | -6.9% | -2722.8% |
| Net Margin | -0.8% | -2732.2% |
| Revenue YoY | -25.7% | 224.0% |
| Net Profit YoY | 97.6% | -82611.5% |
| EPS (diluted) | — | $-5.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $21.4M | ||
| Q3 25 | — | $7.9M | ||
| Q2 25 | $18.7M | $2.5M | ||
| Q1 25 | $50.9M | $3.1M | ||
| Q4 24 | $38.1M | $6.6M | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $25.1M | $7.8M | ||
| Q1 24 | $41.5M | $5.1M |
| Q4 25 | — | $-585.7M | ||
| Q3 25 | — | $-164.0M | ||
| Q2 25 | $-154.0K | $-850.0K | ||
| Q1 25 | $23.5M | $-1.5M | ||
| Q4 24 | $18.9M | $-708.1K | ||
| Q3 24 | $5.7M | — | ||
| Q2 24 | $-6.5M | $-399.6K | ||
| Q1 24 | $13.8M | $-553.2K |
| Q4 25 | — | 78.6% | ||
| Q3 25 | — | 61.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -5.7% | ||
| Q4 24 | — | 17.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 16.8% | ||
| Q1 24 | — | 26.2% |
| Q4 25 | — | -2722.8% | ||
| Q3 25 | — | -39.2% | ||
| Q2 25 | -6.9% | -102.6% | ||
| Q1 25 | 44.4% | -58.3% | ||
| Q4 24 | 46.4% | -13.6% | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | -5.9% | ||
| Q1 24 | 28.1% | -12.2% |
| Q4 25 | — | -2732.2% | ||
| Q3 25 | — | -2063.6% | ||
| Q2 25 | -0.8% | -34.1% | ||
| Q1 25 | 46.2% | -46.5% | ||
| Q4 24 | 49.6% | -10.7% | ||
| Q3 24 | 17.2% | — | ||
| Q2 24 | -26.0% | -5.1% | ||
| Q1 24 | 33.3% | -10.9% |
| Q4 25 | — | $-5.91 | ||
| Q3 25 | — | $-21.86 | ||
| Q2 25 | — | $-0.77 | ||
| Q1 25 | — | $-1.32 | ||
| Q4 24 | — | $-0.64 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.36 | ||
| Q1 24 | — | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $880.9M |
| Total Assets | $175.1M | $892.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $880.9M | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $119.9M | $3.4M | ||
| Q1 25 | $25.0M | $3.6M | ||
| Q4 24 | $-456.0K | $2.3M | ||
| Q3 24 | $-23.5M | — | ||
| Q2 24 | $-31.2M | $1.4M | ||
| Q1 24 | $-31.7M | $1.8M |
| Q4 25 | — | $892.9M | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $175.1M | $8.3M | ||
| Q1 25 | $98.5M | $12.3M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | — | ||
| Q2 24 | $159.2M | $15.2M | ||
| Q1 24 | $184.7M | $15.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-7.9M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.9M | ||
| Q3 25 | — | $-4.5M | ||
| Q2 25 | $-15.8M | $-1.2M | ||
| Q1 25 | $-21.0M | $-537.6K | ||
| Q4 24 | $-19.9M | $-434.3K | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.5M | $436.0K | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-4.5M | ||
| Q2 25 | $-15.8M | $-1.2M | ||
| Q1 25 | $-21.2M | $-539.0K | ||
| Q4 24 | $-20.0M | $-439.7K | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | $426.8K | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -57.0% | ||
| Q2 25 | -84.6% | -50.0% | ||
| Q1 25 | -41.6% | -17.3% | ||
| Q4 24 | -52.5% | -6.6% | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | 5.5% | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | 0.1% | 0.8% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | 0.1% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FWDI
| CODM | $17.4M | 81% |
| Design Segment | $4.1M | 19% |
